Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.
Department of Hematology and Oncology, Marienhospital Herne, University of Bochum, Herne, Germany.International journal of clinical pharmacology and therapeutics (impact factor: 1.18). 01/2012; 50(1):76-8. pp.76-8
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.